A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
Study Details
Study Description
Brief Summary
This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-5788 in healthy adult volunteers. This study will be conducted in 4 parts: a single-ascending dose part, a multiple-ascending dose part, an elderly part and a proof of principle part.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This single centre study will be comprised of 4 parts, Part A (SAD; up to 7 cohorts, 8 subjects per cohort and including an assessment of food effect), a multiple-dose part (up to 4 doses, 10 subjects per cohort); an elderly cohort (8 subjects per gender) and a proof of principle part.
The single ascending dose part (Part A) comprises of increasing doses of an oral solution or capsule, with an investigation of the potential for food effects.
The multiple ascending dose part (Part B, MAD; 14 days dosing) will be initiated after the PK and safety data are available from the single ascending dose part. Subjects in Part B will have ultrasound scans of the gallbladder during the study and at screening a HIDA scan will be performed. An evaluation of the PK in the elderly and any potential gender differences will also be evaluated in Part C. Subjects in Part C will have an ultrasound of the gallbladder at screening.
Part D will be a proof of principle evaluation where the effects of ONO-5788 to inhibit the GHRH and arginine-stimulated GH release will be evaluated. Octreotide acetate is a reference arm in this part of the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ONO-5788 Part A1 Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group |
Drug: ONO-5788
Investigational drug
|
| Placebo Comparator: ONO-5788 Placebo Part A1 Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group |
Drug: ONO-5788 Placebo
Placebo Comparator
|
| Experimental: ONO-5788 Part A2 Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group |
Drug: ONO-5788
Investigational drug
|
| Placebo Comparator: ONO-5788 Placebo Part A2 Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group |
Drug: ONO-5788 Placebo
Placebo Comparator
|
| Experimental: ONO-5788 Part B Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group |
Drug: ONO-5788
Investigational drug
|
| Placebo Comparator: ONO-5788 Placebo Part B Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group |
Drug: ONO-5788 Placebo
Placebo Comparator
|
| Experimental: ONO-5788 Part C Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group |
Drug: ONO-5788
Investigational drug
|
| Placebo Comparator: ONO-5788 Placebo Part C Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group |
Drug: ONO-5788 Placebo
Placebo Comparator
|
| Experimental: ONO-5788 Part D Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine |
Drug: ONO-5788
Investigational drug
|
| Placebo Comparator: ONO-5788 Placebo Part D Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine |
Drug: ONO-5788 Placebo
Placebo Comparator
|
| Active Comparator: Octreotide Part D Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine |
Drug: Octreotide
Active Comparator in Part D
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of participants with treatment emergent adverse events by severity [Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28]
An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possible causal relationship.
- Number of participants with serious adverse events (SAEs) [Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28]
An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged hospitalization, life-threatening experience or persistent disability.
- Number of participants with clinically significant changes in vital signs [Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28]
Number of participants with clinically significant changes in vital signs including pulse/heart rate, respiratory rate, and blood pressure will be reported.
- Number of participants with ECG abnormalities [Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28]
Number of participants with ECG abnormalities will be reported
- Number of participants with clinical laboratory abnormalities [Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28]
Number of participants with clinical laboratory abnormalities will be reported
- Number of participants with clinically significant change in ultrasound of gallbladder [Part B - up to day 21]
Number of participants with clinically significant change in ultrasound of gallbladder will be reported
Secondary Outcome Measures
- Pharmacokinetics (AUC) [Day 1 through Day 14]
Assessment of the plasma area under the curve of ONO-5788 and metabolites (Parts A, B and C only)
- Pharmacokinetics (AUC) - food effect [Day 1]
Effect of food on the plasma area under the curve of ONO-5788 and metabolites (Parts A only)
- Pharmacokinetics (Cmax) [Day 1 through Day 14]
Assessment of the maximum observed plasma concentration of ONO-5788, metabolites (Parts A, B, C & D) and octreotide (Part D only)
- Pharmacokinetics (Cmax) - food effect [Day 1]
Effect of food on the maximum observed plasma concentration of ONO-5788, and metabolites (Part A only)
- Pharmacokinetics (Tmax) [Day 1 through Day 14]
Assessment of the time to reach Cmax for ONO-5788, metabolites (Parts A, B, C & D) and octreotide (Part D only)
- Pharmacokinetics (Tmax) - food effect [Day 1 through Day 14]
Effect of food on the time to reach Cmax for ONO-5788, metabolites (Part A only)
- Pharmacokinetics (Ctrough) [Day 1 through Day 14]
Assessment of trough levels for ONO-5788 and metabolites immediately before dosing (Part B only)
- Pharmacokinetics (T1/2) [Day 1 through Day 14]
Assessment of the elimination half-life of ONO-5788 and metabolites (Parts A, B and C only)
- Pharmacokinetics (T1/2) - food effect [Day 1]
Effect of food on the elimination half-life of ONO-5788 and metabolites (metabolite) (Part A only)
- Pharmacokinetics (CL/F) [Day 1]
Assessment of the apparent clearance rate of ONO-5788 (Parts A & C)
- Pharmacokinetics (CL/F) - food effect [Day 1]
Effect of food on the apparent clearance rate of ONO-5788 (Part A only)
- Pharmacokinetics (Cave) [Day 1]
Average concentration of ONO-5788/metabolites/Octreotide (Part D only)
- Pharmacodynamics (IGF-1) [Day 1 through Day 21]
Assessment of the effects of ONO-5788 on IGF-1 levels (Part B only)
- Pharmacodynamics (Growth Hormone) [Day 1 through Day 21]
Assessment of the effects of ONO-5788 on GH levels (Part B)
- Pharmacodynamics (Growth Hormone) [Day 1]
Assessment of the effects of ONO-5788 on GHRH & arginine stimulated GH levels (Part D)
- Pharmacodynamics (IGFBP3) [Day 1 through Day 21]
Assessment of the effects of ONO-5788 on IGFBP3 levels (Part B only)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy, adult, male and female (women of non-child bearing potential, surgically sterile) volunteers, 18-55 years of age, inclusive, at screening (Parts A & B only).
-
Healthy, adult, males and female (women of non-child bearing potential), ≥65 years of age at screening (Part C only).
-
Healthy, adult, male, 18-40 years of age, inclusive, at screening (Part D only).
-
Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECG abnormalities (All Parts).
-
Body mass index (BMI) of ≥18.5 to ≤30 kg/m2 at screening (Parts A, B & C).
-
Body mass index (BMI) of ≥18.5 to <25 kg/m2 at screening (Part D only).
Exclusion Criteria:
-
History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
-
History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
-
History or presence of hypersensitivity or idiosyncratic reaction to the study drugs,excipients or related compounds.
-
History or presence of:
-
Gallstones, cholangitis, and/or cholecystitis or clinically significant findings on gallbladder ultrasound as determined by the Principal Investigator;
-
Pancreatitis;
-
Hypothyroidism;
-
Known diabetes mellitus type 1 or type 2;
-
Hypocalcaemia or hypokalemia;
-
Hypoglycemia or hyperglycemia or fasting blood glucose outside normal local range;
-
Thrombocytopenia or other clinically significant hematologic abnormalities;
-
Inflammatory bowel disease, irritable bowel syndrome, or abdominal surgery;
-
Known vitamin B12 deficiency.
-
Abnormal gallbladder ejection fraction on hepatobiliary iminodiacetic acid (HIDA) scan at screening (Part B only)
-
Positive urine drug, alcohol or cotinine results at screening or check in.
-
Clinically significant serum electrolyte (sodium, potassium, chloride, bicarbonate) abnormalities at screening or each check-in, in the estimation and clinical judgment of the PI or designee.
-
Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
-
Seated blood pressure is less than 90/40 millimeter of mercury (mmHg) or greater than 140/90 mmHg (160/95 mmHg for Part C) at screening.
-
Has engaged in strenuous physical exercise in the 48 hours prior first dosing or intends to undergo strenuous physical exercise at any time throughout the study.
-
Donation of blood or significant blood loss within 56 days prior to the first dosing.
-
Plasma donation within 7 days prior to the first dosing.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Celerion | Tempe | Arizona | United States | 85283 |
Sponsors and Collaborators
- Ono Pharmaceutical Co. Ltd
Investigators
- Principal Investigator: Terry O'Reilly, MD, Celerion
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ONO-5788-01